Compare ONC & GFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | GFI |
|---|---|---|
| Founded | 2010 | 1887 |
| Country | Switzerland | South Africa |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precious Metals |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 35.5B |
| IPO Year | 2015 | 2002 |
| Metric | ONC | GFI |
|---|---|---|
| Price | $416.47 | $35.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 27 | 8 |
| Target Price | ★ $465.00 | $46.84 |
| AVG Volume (30 Days) | 442.0K | ★ 3.6M |
| Earning Date | 11-05-2026 | 08-25-2026 |
| Dividend Yield | N/A | ★ 5.27% |
| EPS Growth | ★ 140.43 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $238,387,000.00 | N/A |
| Revenue This Year | $29.05 | $36.55 |
| Revenue Next Year | $15.06 | $3.34 |
| P/E Ratio | $743.85 | ★ $25.02 |
| Revenue Growth | ★ 22179.16 | N/A |
| 52 Week Low | $253.95 | $31.11 |
| 52 Week High | $424.73 | $61.52 |
| Indicator | ONC | GFI |
|---|---|---|
| Relative Strength Index (RSI) | 67.27 | 46.14 |
| Support Level | $341.67 | $34.67 |
| Resistance Level | N/A | $38.15 |
| Average True Range (ATR) | 10.70 | 1.20 |
| MACD | 4.37 | 0.21 |
| Stochastic Oscillator | 88.77 | 38.65 |
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia, and Peru. In Peru, the company also produces copper. The company is involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing, and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith, and South Deep, and surface-only open pit mining at Damang, Tarkwa, and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.